While we used the same monoclonal antibody for PD‐L1 in both primary and metastatic tumors, we used different antibodies for PD‐1 due to the availability of a commercial antibody to human PD‐1 at the time each cohort was analyzed. Here, CD274 is linked to metastatic neoplasm.